Morgan Stanley Initiates Coverage On Bicara Therapeutics with Overweight Rating, Announces Price Target of $35

Benzinga · 10/08 11:25
Morgan Stanley analyst Judah Frommer initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Overweight rating and announces Price Target of $35.